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Abstract
Multiplex cancer genetic testing by next generation sequencing (NGS) offers genetic
counselors and patients new options for testing multiple genes beyond BRCA1 and
BRCA2, increasing both the yield of positive results and the number of variants of
uncertain significance (VUS). This pilot study explored three psychosocial questions
related to multiplex cancer genetic testing: 1). Do anxiety levels differ in patients with
results of familiar single gene testing versus those with results of multiplex cancer
genetic testing of unfamiliar genes? 2). Do different results (i.e., negative, positive, or
VUS) affect patient anxiety levels in the post-results period? 3). Is patient anxiety
affected by the specific gene in which the mutation or VUS is identified? The study
included women diagnosed with breast cancer and considered at high risk for a hereditary
cancer syndrome due to age or family history. Participants completed a baseline StateTrait Anxiety (STAI) questionnaire at the pre-test genetic counseling session, and
completed the same STAI questionnaire and a Multidimensional Impact of Cancer Risk
Assessment (MICRA) questionnaire after the post-results discussion. Twenty individuals
participated, of which 17 patients completed the baseline STAI tool. Nine participants
completed all questionnaires, yielding five participants with negative results, two with
positive results, and two with VUS results. Two participants with negative results showed
significant baseline anxiety levels which decreased in the post-results period. The
positive and VUS result groups showed non-significantly increased mean anxiety levels
by STAI. Differences in anxiety between those with positive results and those with
iii

negative results trended toward significance. Two individuals with positive mutation
results in genes other than BRCA1 and BRCA2 showed higher post-results anxiety levels
on the MICRA scale than did two participants with VUS results. The study was limited
by sample size. A larger multi-site study is planned to clarify anxiety, distress, and
uncertainty parameters to help guide genetic counselors in their approach to psychosocial
aspects of multiplex cancer genetic testing.
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Chapter 1: Background
1.1 Cancer and Hereditary Breast and Ovarian Cancer Syndrome
As described by the National Cancer Institute, cancer is a common condition within the
context of all human illness (National Cancer Institute, 2014b). Cancer can affect any
person, often in a seemingly random fashion in an isolated individual, and occasionally in
a pattern affecting several members across multiple generations of a single family. The
development of cancer can be grouped into three classifications by etiology, including
sporadic, familial, and hereditary cancers. The majority of cancers (70% to 80%) occur
sporadically, and are ultimately due to a combination of environmental exposures and
chance cellular events culminating in unchecked cell proliferation through eventual
accumulation of one or, more likely, numerous genetic changes (Vogelstein & Kinzler,
2004). Approximately 15-20% of people who develop cancer have a family member with
the same cancer, typically at older age of onset, thereby displaying a familial pattern,
which could be attributed to shared genetics and other factors like dietary practices and
similar environmental exposures. Five to ten percent of breast cancer cases are caused by
an inherited germline mutation in a specific gene that confers an increased lifetime
susceptibility to cancer development (USPSTF, 2009).
The most common genes currently known to be associated with a significantly
increased lifetime risk for breast cancer are the BRCA1 and BRCA2 genes. The estimated
carrier frequency among women of Northern European descent for deleterious mutations
is approximately one in 400. The frequency of pathogenic mutations varies across ethnic
1

groups, ranging from between one in 250 and one in 840 (Anglian Breast Cancer Study
Group, 2000; Antoniou et al., 2002; Narod & Foulkes, 2004). The most frequently
affected group is the Ashkenazi Jewish population where three founder mutations
identified in this group account for approximately 99% of BRCA1 and BRCA2 mutations.
Carrier frequency of BRCA1 or BRCA2 mutations in women of this ancestry occurs in
one out of every forty individuals (Oddoux et al., 1996; Offit et al., 1996).
The effects of various deleterious mutations in these two genes lead to a condition
known as Hereditary Breast and Ovarian Cancer syndrome (HBOC). Findings in a family
history characteristic of HBOC include early age of onset (diagnosis under age 50),
bilateral breast cancer, and possibly multiple primary cancers. Additionally, HBOC can
present with a family or personal history of one or more different forms of cancer which
may include ovarian cancer, male breast cancer, pancreatic, prostate, fallopian tube,
and/or primary peritoneal cancers (National Cancer Institute, 2014a). These genes are
considered highly penetrant, as the estimated cumulative lifetime risk for breast cancer is
up to 87% for BRCA1 mutation carriers and up to 84% for BRCA2 mutation carriers by
age 70 (Ford et al., 1998; Ford, Easton, Bishop, Narod, & Goldgar, 1994). Furthermore,
the risk for a second primary breast cancer within five years of a first diagnosis is 20%
for BRCA1 mutation carriers and 12% for BRCA2 mutation carriers (Verhoog et al.,
1999). BRCA1 mutation carriers have also been shown to have up to a 44% risk of
developing ovarian cancer (Ford et al., 1994), while BRCA2 mutations carriers have up
to a 27% risk of developing ovarian cancer over their lifetimes (ford et al., 1998). Much
progress has been documented in publications about our increasing understanding of the
mechanisms by which mutations within the BRCA1 and BRCA2 genes predispose an
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individual to the development of breast and other cancers (Rebbeck et al., 2015; Konishi
et al., 2011; Miki et al., 1994).
The National Cancer Institute has described several models which predict the
likelihood of a germline mutation in BRCA1 or BRCA2 in an individual or family
(National Cancer Institute, 2014a). Two models exist which estimate risk of mutation
using Bayesian analysis, employing formulation of a probability estimate based on the
incorporation of familial evidence (i.e., family history of cancer or lack thereof), namely
BRCAPRO (Parmigiani, Berry, & Aguilar, 1998) and BOADICEA (Antoniou, Pharoah,
Smith, & Easton, 2004; Mavaddat, Rebbeck, Lakhani, Easton, & Antoniou, 2010). Both
BRCAPRO and BOADICEA have been upgraded since their development to incorporate
breast tumor immunohistochemical markers such as hormone receptor status (Biswas et
al., 2012; Tai, Chen, Parmigiani, & Klein, 2008). Other models, such as the LAMBDA
model for predicting the mutation carrier risk of Ashkenazi Jewish women, the modified
Penn model (also known as Couch tables), and the Shattuck-Eidens model rely solely on
logistic regression (Apicella et al., 2007; Couch et al., 1997; Evans et al., 2004; Frank et
al., 1998, 2002; Shattuck-Eidens et al., 1997).
Some risk models rely on empiric observation, the most well-known of which are
the prevalence tables presented by Myriad Genetics Laboratory, which use approximately
169,000 patient results acquired up to 2010 to predict the likelihood of a pathogenic
mutation being present given specific conditions in the patient and in her close family
members (Malone et al., 2006; Risch et al., 2001; Struewing et al., 1995; Warner et al.,
1999). Empiric risk tables have several limitations. Tables often do not capture other
cancers which can be associated with BRCA1 and BRCA2 mutations, such as pancreatic

3

and prostate cancer. Additionally, a table may fail to account for risk reduction surgeries
such as prophylactic mastectomy and oophorectomy or for limited family history (Katki,
2007; Weitzel et al., 2007). Furthermore, empiric prediction models may underestimate
or misrepresent the risk to minority groups such as Asian (Kurian et al., 2008), AfricanAmerican, and Hispanic populations (Kurian et al., 2009; Vogel et al., 2007).
1.2 Other Breast Cancer Predisposition Genes
Beyond BRCA1 and BRCA2, mutations in several other genes are associated with
an increased lifetime risk of breast cancer. Deleterious TP53 mutations have been
identified as the cause for Li-Fraumeni syndrome (LFS), a condition classically
associated with an increased lifetime risk for sarcoma, brain tumors, breast cancer,
leukemia, and adrenocortical carcinoma, frequently at young ages (Malkin et al., 1990;
Nichols, Malkin, Garber, Fraumeni, & Li, 2001). A broader range of LFS associated
tumors can include lymphomas, gastrointestinal malignancies, melanoma, and lung
cancers, all of which have been documented in families with known TP53 mutations
(Gonzalez, Noltner, et al., 2009). The risk of an individual with a deleterious TP53
mutation developing cancer by age 45 is up to 84%, with a lifetime risk of at least one
type of cancer developing by age 85 at up to 100% (Ruijs et al., 2010). A report by Walsh
et al. (2006) found that mutations within the TP53 gene account for approximately 1% of
breast cancers in families with histories consistent with HBOC syndrome that lacked
identifiable deleterious mutations in either BRCA1 or BRCA2. Diagnostic criteria for
“classic LFS” includes a proband with a sarcoma under the age of 45 with a first-degree
relative with cancer prior to age 45, and an additional first- or second-degree relative with
cancer diagnosed before age 45, or with a sarcoma at any age (Li et al., 1988). The
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Chompret criteria proposed in 2001 includes three possible diagnostic criteria, any one of
which were considered sufficiently appropriate to test an individual for a germline
mutation in the TP53 gene:
1) a proband diagnosed with a tumor in the LFS tumor spectrum before
the age of 46 (these tumors being defined as soft-tissue sarcoma,
osteosarcoma, pre-menopausal breast cancer, brain tumor, adrenal cortical
carcinoma, leukemia, or lung cancer) and one or more first- or seconddegree relative with a LFS-related tumor below the age of 56, or
2) a proband with multiple LFS-related tumors (excluding multiple breast
tumors), two of which belong to the LFS tumor spectrum, with the initial
cancer occurring before the age of 46, or
3) a proband diagnosed at any age with adrenal cortical carcinoma or a
tumor of the choroid plexus, regardless of family history (Chompret et al.,
2001, p. 46).
Current NCCN guidelines state that in an individual with breast cancer
diagnosed at or under the age of 35 years, TP53 mutation testing can be ordered
alone, concurrently with BRCA1/2 testing and/or other gene testing or as a followup test after negative BRCA1/2 testing.(NCCN, 2015).
Deleterious mutations within the PTEN gene have been identified as one cause of
Cowden syndrome, although many individuals who meet clinical criteria for Cowden
syndrome are not found to carry a deleterious PTEN mutation (Pilarski, Stephens, Noss,
Fisher, & Prior, 2011). Approximately 85% of patients with a clinical diagnosis of
Cowden syndrome are found to carry a deleterious mutation within the PTEN gene (Zhou
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et al., 2003). Genetic testing for cancer predisposition syndromes, especially with the use
of recent multiplex molecular testing, has shown that the phenotype associated with
PTEN mutations varies greatly. With no truly ubiquitous phenotype, the diagnostic
criteria for Cowden syndrome requires amending, should it hope to erase any ambiguity
between clinical diagnoses and molecular diagnoses of Cowden syndrome (Pilarski et al.,
2013). With the condition’s highly variable expression, it is unlikely that any clinical
criteria could completely eliminate discrepancies between molecular and clinical
diagnoses (R. Pilarski, personal communication, February, 2015). Cowden syndrome has
been associated with benign but clinically significant features including oral papillomas,
facial trichilemmomas, macrocephaly, uterine fibroids, and fibrocystic breasts (Nelen et
al., 1996). Additionally, the condition is often associated with increased lifetime risks for
cancers of the breast (25% to 50%), thyroid (10%), and endometrium (5%) (Bubien et al.,
2013; Tan et al., 2012). Median onset of PTEN-related cancers occurs at 33 years of age,
with one-third of all PTEN-related breast cancers occurring before age 30 (Birch et al.,
1994; Olivier et al., 2003).
Mutations within the STK11 gene have been identified as a cause of Peutz-Jeghers
syndrome. Peutz-Jeghers syndrome is associated with large hamartomatous
gastrointestinal polyps, mucocutaneous pigmentation changes, and increased lifetime risk
of cancers of the breast (32 to 54%), colon (39%), stomach (29%), pancreas (11 to 36%),
lungs (7 to 17%), ovaries (21%), and testicles (9%) (Giardiello et al., 2000; Hearle et al.,
2006; McGarrity, Amos, Frazier, & Wei, 2013; van Lier et al., 2010).
Mutations within the CDH1 gene have been shown to cause hereditary diffuse
gastric cancer, which leads to a 70% lifetime risk of gastric cancer and a 60% lifetime
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risk of lobular breast cancer (Guilford et al., 1998). Intervention for screening and
diagnosis of CDH1-related cancers is warranted base on the gene and its significant risk
level for developing breast and gastric cancers (NCCN, 2015).
These hereditary cancer syndromes, including HBOC syndrome, are inherited in
an autosomal dominant manner, meaning that the inheritance of only one mutated copy of
the gene is sufficient to confer a significantly increased susceptibility of developing
breast and other cancers across an individual’s lifetime. Thus, identifying a deleterious
mutation in any of these genes in an individual has important clinical implications for that
individual’s close relatives regarding genetic testing and possible medical management.
Mutations in other genes have been linked to a genetic predisposition to breast
cancer. Some of these genes include at least ATM, CHEK2, PALB2, STK11, NBN,
BARD1, MRE11A, RAD51C, and BRIP1 genes. PALB2 has been found to bind directly to
BRCA2, both genes working in concert within a broader gene commplex to repair double
stranded DNA breaks (Oliver, Swift, Lord, Ashworth, & Pearl, 2009; Xia et al., 2006). A
recent study by Antoniou et al. (2014) showed that breast cancer risk in women with a
PALB2 deleterious mutation is significantly influenced by family history. They reported
that the absolute risk of developing breast cancer ranged from 33% by age 70 in an
individual with no family history of breast cancer, up to at least 58% by age 70 in a
woman who has two or more first-degree relatives with breast cancer diagnosed by age
50 years.
Mutations within the CHEK2 gene confer an increased lifetime risk of breast
cancer of about 23% to 48% based on susceptibility due to the founder mutation,
CHEK2*1100del C, in individuals of Northern and Eastern European descent. Due to this
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mutation which results in a truncated protein, carriers also have a significantly increased
risk of a second breast cancer (Weisher et al., 2012). In their study of over 25,000 women
with breast cancer, 1.8% were found to carry this mutation. Additionally, mutations
within the CHEK2 gene confer an increased lifetime risk for colorectal cancer that is
estimated at about 7.2% to 9.5% by a meta-analysis reported by Xiang, Geng, Ge, & Li
(2011).
Homozygous mutations within the ATM gene have previously been associated
with ataxia-telangiectasia, an autosomal recessive disorder that presents with childhood
onset of progressive neurodegeneration, telangiectasia, immunodeficiency, gonadal
atrophy, and a predisposition to malignant tumor growth (Morrell, Cromartie, & Swift,
1986). Heterozygous carriers of mutations within the ATM gene have an elevated risk of
developing breast cancer, with a lifetime risk of approximately 17% to 52% (Ahmed &
Rahman, 2006; Swift, Morrell, Massey, & Chase, 1991; Thompson et al., 2005).
Germline mutations within the NBN gene lead to a higher incidence of childhood
onset acute lymphoblastic leukemia. When inherited in a homozygous manner,
deleterious mutations in both alleles of the NBN gene can cause Nijmegen breakage
syndrome, a condition which causes microcephaly, short stature, immunodeficiency, and
increased chance of malignant tumor growth (Varon et al., 1998; Varon et al., 2001).
Other deleterious mutations in the NBN gene have been recently reported to cause an
increased susceptibility to breast cancer in small numbers of patients (Damiola et al.,
2014; Kurian et al., 2014) and individual cases (E. Jordon, personal communication,
November, 2014). The lifetime risk in women who carry an NBN deleterious mutation is
estimated to be up to 30% by age 80, with the most common variant, c.657del5, acting as
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a founder mutatioin in patients of Slavic ancestry. This mutation is known to confer an
approximately 30% lifetime risk for breast cancer in the Eastern European population
(Steffen et al., 2006; Zhang, Beeghly-Fadiel, Long, & Zheng, 2011). Additionally,
individual polymorphisms in the NBN gene as, reported by Berardinelli, di Masi, &
Antoccia (2013), have been associated with small increased lifetime risks for basal cell
carcinoma, leukemia, lymphoma, melanoma, medulloblastoma, and cancers of the
bladder, colon, liver, ovaries, ovaries, prostate, kidneys, and lungs . There are no
currently widely accepted guidelines for the medical management of individuals with an
NBN mutation.
Cancer susceptibility conferred by the BARD1, MRE11A, RAD50, RAD51C, and
BRIP1 genes is not well defined and relies heavily on case studies or sequencing studies
of limited size. Additional segregation studies and collaborative case-control studies are
required to further define the associated cancer risks for of these genes (Bartkova et al.,
2008; Ellis & Offit, 2012; Rainville & Rana, 2014; Seal et al., 2006; Southey et al.,
2013). At this time, intervention for breast cancer screening and diagnosis is not
recommended due to insufficient evidence for intervention based on mutations in these
genes. However, intervention may still be warranted based on family history or other
clinical factors (NCCN, 2015). One example is the BRIP1 gene, in which mutations were
reported to confer a high risk (up to 8.3%) of ovarian cancer (Rafnar et al., 2011). In one
family, an unaffected female with family history of two close relatives diagnosed with
primary peritoneal cancer was found to carry a deleterious BRIP1 mutation. She elected
prophylactic surgery (bilateral salpingo-oophorectomy) as likely risk-reduction
management (P. Walker, personal communication, September, 2014).
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1.3 Sequencing Options
Since 1977, the gold standard for sequencing genetic information has been Sanger
sequencing, a method of DNA sequencing which utilizes chain-terminating inhibitors of
DNA polymerase to determine a nucleotide sequence (Sanger, Nicklen, & Coulson,
1977). The capacity of this method is typically up to 96 sequences of approximately 400500 nucleotides per run (Shendure, Mitra, Varma, & Church, 2004). Historically, DNA
sequencing of the BRCA1 and BRCA2 gene were completed by Sanger sequencing. This
technique requires bases be added one by one, leading to a relatively time-consuming and
costly process. For this reason, genetic testing for any of the known hereditary cancer
syndromes was most often limited to typically only one or two genes at a time and was
available at a high cost when Myriad Genetics Laboratory, first began offering
commercial sequencing of BRCA1 and BRCA2 in 1996 (Gold & Carbone, 2010).
In 2005, Margulies et al. at 454 Life Sciences Corp introduced a new method of
sequencing, which utilized massive parallel sequencing technologies to sequence up to 25
million bases in a single run (Margulies et al., 2005). This method offered an
approximately 100-fold increase in throughput over traditional Sanger sequencing
methods and laid the framework for multiple contemporary sequencing technologies with
competitive throughput, all called next generation sequencing (NGS) (Schuster, 2008;
Vogelstein et al., 2013). NGS has demonstrated the advantage of offering much shorter
read lengths when compared to Sanger sequencing, and can process far more sequences
in a single run, allowing for the processing of several genes or even a patient’s entire
genome with 90% to 95% coverage (Cirulli et al., 2010; Wheeler et al., 2008).
Additionally, turn-around-time is considerably shorter using NGS due to its multiplex
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configuration of sequencing reactions. However, one possible limitation to consider is
coverage of specific regions by NGS which can be affected by repetitive nucleotide
content as well as GC-rich content (Rehm et al., 2013).
Myriad Genetics Laboratory initially held patents on both BRCA1 and BRCA2
which lasted until about 2012. With the 2013 Supreme Court decision (Association for
Molecular Pathology et al. v. Myriad Genetics, Inc., 2014) and competing technological
advancements, i.e., NGS technology, the possibility of multiplex cancer molecular testing
has now become a reasonable clinical tool offered by multiple companies to identify
which patients carry a hereditary deleterious mutation in one of numerous genes that can
significantly increase their risk of developing breast cancer. The legal decision and this
technological shift have enabled a change in in BRCA1 and BRCA2 hereditary cancer
testing. Patients and healthcare professionals can now consider whether testing only the
genes most often associated with an increased lifetime risk for breast cancer (BRCA1 and
BRCA2), or testing all clinically actionable genes currently known to be associated with
breast cancer predisposition syndromes is more appropriate (Rehm et al., 2013).
Multiplex cancer molecular testing can also include genes associated with cancer
development in other parts of the body not associated with HBOC, but with overlapping
susceptibilities to common cancers. For example, a colon cancer gene panel for Lynch
syndrome can include MLH1, MSH2, MSH6, PMS2, and EPCAM. The typical phenotype
of Lynch syndrome overlaps with HBOC syndrome through a significantly increased
lifetime risk of ovarian cancer. Lynch syndrome may also increase the lifetime risk for
breast cancer (Buerki et al., 2012; Win, Lindor, & Jenkins, 2013), but that remains illdefined (Cohen & Leininger, 2014). Current comprehensive multigene cancer genetic
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testing offerings for hereditary breast and hereditary ovarian cancers now may include
some or all of the genes associated with increased susceptibility of breast and/or ovarian
cancer if a deleterious mutation exists.
With the discovery of multiple additional genes associated with inherited cancer
predisposition syndromes, various researchers have attempted to estimate the de novo
mutation rate among these genes. In a single study of 193 patients with sporadic breast
cancer, one patient was found to have a single new mutation in the BRCA1 gene,
suggesting from this small study that the de novo mutation rate for BRCA1 and BRCA2
may be low, likely less than 5% (De Leeneer et al., 2012). Conversely, the de novo rates
among the PTEN, STK11, and TP53 genes are thought to be much higher, approximately
within the range of 10% to 30% de novo mutation rate (Gonzalez, Buzin, et al., 2009;
Schreibman, Baker, Amos, & McGarrity, 2005; Westerman et al., 1999). Through
sequencing of one or more genes, de novo mutations that cause either a loss of function
or gain of function can be detected within the gene that may interfere with its
functionality and may explain some apparently isolated cases of early-onset “hereditary”
breast cancer in an individual with no family history of the disease.
1.4 Management and Anxiety
Healthcare providers, particularly genetic counselors, typically understand which
patients are the best candidates for genetic testing, given the guidance provided by NCCN
and other professional societies which issue their own guidelines for possible genetic
testing of women with breast cancer. Healthcare providers who are ordering genetic
testing in today’s breast cancer genetic environment must consider the most appropriate
testing for each patient. Among populations where the carrier rate for deleterious BRCA1
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and BRCA2 mutations is highest, and in which there are known common mutations, such
as the Ashkenazi Jewish population, population-based screening for the three most
common mutations has been found to be the most cost-effective first step in genetic
testing (Manchanda et al., 2015) and is supported by the current NCCN guidelines
(NCCN, 2015). In all cases, the patient’s personal medical history and a three-generation
family history with identification of ancestry are recommended to help guide the
healthcare provider in providing an accurate risk assessment for the patient (NCCN,
2015), which then leads to an appropriate decision about testing and which type of
testing, e.g., single gene analysis of BRCA1/2, or a more comprehensive multiplex
analysis of multiple susceptibility genes as described above.
Molecular testing for breast cancer predisposition syndromes often influences
healthcare decisions involving risk-reducing surgical measures. Because individuals who
carry a pathogenic mutation in either the BRCA1 or BRCA2 are at significantly increased
risk for developing breast or ovarian cancer, many women opt to undergo risk-reducing
bilateral mastectomies and/or risk-reducing bilateral salpingo-oophorectomy (BSO).
Prophylactic mastectomies have been shown to reduce the risk of breast cancer by about
90% (Rebbeck et al., 2004), while prophylactic BSO has been shown to reduce the risk
for ovarian cancer by up to 96% (Chang-Claude et al., 2007). This surgery has been
reported to also reduce the risk for breast cancer by about 50% when performed in
premenopausal women (Eisen et al., 2005; Kauff et al., 2008; Rebbeck et al., 1999;
Rebbeck, Kauff, & Domchek, 2009). The benefits of prophylactic mastectomy are further
evidenced by a reduction in mortality among women with BRCA1/BRCA2 associated
breast cancer (Evans et al., 2013).
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In the past decade, uptake of risk-reducing surgical intervention has increased
among unaffected BRCA1/BRCA2 carriers and non-carriers with a strong family history
of breast cancer. Community-based physicians have begun incorporating BRCA1/BRCA2
testing into their practice. In 2008, Keating, Stoeckert, Regan, DiGianni, & Garber
reported that geneticists and gynecologists were less likely than medical oncologists and
surgeons to recommend prophylactic mastectomy among unaffected women with a
known BRCA1 mutation. Uptake of risk-reducing surgery was reported to be dependent
on factors such as lifetime risk, age, and time since testing (Evans et al., 2009), with the
strongest influencing factor being a negative or positive genetic test result (Hawley et al.,
2014). Another influential factor reported among unaffected carriers was having a family
history of death(s) due to cancer. Those who had experienced the death of a relative due
to cancer perceived breast cancer as having a “stronger identity” with more “dire
consequences” and as being “uncontrollable” when compared to carriers who had not
experienced the death of a relative (Samama, Hasson-Ohayon, Perry, Morag, &
Goldzweig, 2014).
Differences in uptake between risk-reducing mastectomy and BSO are partially
dependent on results of genetic testing, as women who receive an uninformative result
from genetic testing were less likely to see the positive aspects of risk-reducing
oophorectomy than those who received a positive result (O’Neill et al., 2010).
Regardless, a minority of unaffected women who received an uninformative result from
BRCA1/BRCA2 testing still underwent risk-reducing surgery, with 6.8% undergoing riskreducing mastectomies and 13.3% undergoing risk-reducing BSO (Schwartz et al., 2012).
Factors associated with uptake of risk-reducing mastectomy and oophorectomy included
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perceived risk of breast and ovarian cancer, education, age, marital status, and perceived
risk of carrying a BRCA1/BRCA2 mutation despite receiving uninformative results. This
finding underscores the critical need for comprehensive pre-test and post-test counseling
(Tong et al., 2014).
Genetic testing may or may not return a clear answer as to the genetic cause of a
patient’s hereditary susceptibility to cancer. Possible results can include a negative
finding in any gene tested, a known deleterious mutation (positive result), or a variant of
uncertain significance (VUS). Negative findings are considered uninformative when the
individual tested is the first person in the family to be tested, or when an unaffected
person with cancer in the family without previous genetic analysis if tested. While a
negative result can be reassuring, limitations exist that do not completely rule out the
possibility of a mutation exists in the family but could not be detected. A true negative
result is reported only in the circumstance where a deleterious mutation is known to exist
within the patient’s family, but the specific mutation was not found within the relative
who underwent testing specifically for the known familial mutation.
As is typically explained in a genetic counseling session, a negative result does
not conclusively rule out the possibility of a hereditary cancer predisposition syndrome
for several reasons. Negative testing for a familial mutation does not rule out the
possibility of other findings, such as a mutation other than what is being specifically
tested for, or a finding in a different gene. Regions exist within every gene that cannot be
sequenced, leading to residual risk for deleterious mutations among genes sequenced
despite negative results. Negative BRCA1 and BRCA2 results do not rule out the
possibility of changes within other genes known to cause an increased lifetime risk for
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breast cancer. Likewise, negative genetic testing results also do not exclude the
possibility of increased risk due to mutations in currently undiscovered genes, low-risk
susceptibility genes, or gene-environmental interactions (Mincey, 2003) or possible
epigenetic changes to the gene of interest.
The risk of having a VUS result returned is considerably increased when testing
multiple genes (Hilbers, Vreeswijk, van Asperen, & Devilee, 2013). The International
Agency for Research on Cancer (IARC) supports a common classification system which
would facilitate standardized categorization of VUS results by statistical models of
pathogenicity (Goldgar et al., 2008; Thompson et al., 2014). Five classes of possible
findings exist as follows:
Class 1: negative;
Class 2: likely not pathogenic (i.e., likely benign);
Class 3: uncertain pathogenicity, i.e., variant of uncertain significance (VUS);
Class 4: likely pathogenic; or
Class 5: positive (i.e, pathogenic).
Classification of a finding into one of the above categories often requires statistical
analysis by activity models (Guidugli et al., 2014). Reclassification of a VUS may be
simplified by an accurate and detailed family history if several affected relatives are
found to have the same variant. While counseling regarding clinical management for a
known deleterious mutation is typically well-defined for the most well understood cancer
predisposition genes, guidelines for clinical management for VUS results are not
available and medical management is advised to be based on the individual’s personal
and family history without consideration of the VUS report. In these situations,
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information regarding penetrance is limited, sometimes solely to the individual’s family
history. Counseling regarding screening and risk reduction must be individualized to the
patient in these situations (Plon et al., 2008).
Another step in the process of genetic counseling is to assess the level of anxiety
in patients and assist in their understanding and adaptation to their genetic test results
(Resta et al., 2006). Negative test results have been shown to significantly reduce
perceived risk and distress when compared to those patients who receive a positive
mutation result (Croyle, Smith, Botkin, Baty, & Nash, 1997; Schwartz et al., 2002).
Patients who receive a positive result typically experience heightened distress after
disclosure concerning their risk for cancer, while non-carriers have been shown to have
decreased psychological distress (Meiser et al., 2002; van Roosmalen et al., 2004).
Prolonged intervention rather than a single informational session is a better strategy for
reducing distress and meeting information needs in the case of a positive result (White et
al., 2014). Patients with an uncertain result, defined as -a VUS, have been shown to have
increased anxiety related to testing (O’Neill et al., 2009), but markedly less than those
who receive a positive result (Smith et al., 2008). Additionally, patients who receive
uncertain results have been shown to experience decisional conflicts regarding
prophylactic measures for risk reduction (Rini et al., 2009). While patients with a VUS
result are more likely to overestimate their associated cancer risk than patients who
receive a positive result, they are also more likely to have infrequent screening compared
to those who receive a positive result (Vos et al., 2012).
As discussed previously, a positive finding or a VUS can be detected in any gene
being sequenced and can often influence patient misunderstandings of the results, causing
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anxiety and distress. These results may complicate medical recommendations as VUS
results do not influence medical recommendations for management. As Domchek,
Bradbury, Garber, Offit, & Robson (2013) stated, the likelihood of detecting a VUS is
directly related to the number of genes being sequenced. Therefore, multiplex testing
presents a significant risk of yielding uncertain results as multigene testing can currently
include up to 40 genes depending on the test provider. VUS results are more likely to
generate inappropriate recommendations regarding patient care by the physician (Plon et
al., 2011). Richter et al. therefore recommend that the field would benefit from additional
education for referring physicians to make them aware of the possibility of VUS results
and the clinical uncertainty they can present (2013). Furthermore, formal risk
assessments should be based on the counselee’s personal and family cancer history and
should not be affected by VUS results, as uncertain results do not significantly decrease
the probability of cancer within families with a significant history of cancer (Gadzicki et
al., 2011; Plon et al., 2011). Healthcare providers should work to establish VUS-related
guidelines for disclosure, management, and follow-up, as no clear risk guidelines
presently exist (Gadzicki et al., 2011; Richter et al., 2013).
This pilot study explored the differences between anxiety levels for patients who
participated in classic single-gene genetic testing for HBOC due to BRCA1 and BRCA2
mutations associated with breast cancer, compared with those who chose cancer genetic
testing by multigene panels for inherited breast cancer predisposition syndromes. The
study explored three areas: the overall anxiety changes associated with classic genetic
testing versus expanded panel testing; how negative, positive, or VUS results can
differentially affect anxiety; and how patient anxiety is affected by the gene in which a
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genetic change was found. We hypothesized that a positive or VUS finding within a gene
other than BRCA1 or BRCA2 will induce increased anxiety over anxiety measured due to
a positive or VUS finding in BRCA1 or BRCA2, as these are the classically “expected”
genes for breast cancer predisposition syndromes. If we find that anxiety levels differ
significantly depending upon which gene gives a negative, positive, or VUS result, this
psychosocial information could be of value in influencing how genetic counselors and
other medical professionals discuss genetic testing options. The information gained by
this pilot study is expected to be beneficial for healthcare providers and their patients, if
proven in an upcoming multisite study that we anticipate will demonstrate significantly
different levels of anxiety dependent on the above factors. Gaining a better understanding
of how multiplex genetic test results can influence levels of anxiety will benefit genetic
counselors and their patients, as genetic counselors can then better address patient’s
concerns and anxiety more specifically in future sessions.
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Chapter 2: Manuscript
Evaluating Changes in Patient Anxiety Regarding Classic Cancer Genetic Testing
Versus Expanded Multiplex Cancer Genetic Testing1
2.1 Abstract
Multiplex cancer genetic testing by next generation sequencing (NGS) offers genetic
counselors and patients new options for testing multiple genes beyond BRCA1 and
BRCA2, increasing both the yield of positive results and the number of variants of
uncertain significance (VUS). This pilot study explored three psychosocial questions
related to multiplex cancer genetic testing: 1). Do anxiety levels differ in patients with
results of familiar single gene testing versus those with results of multiplex cancer
genetic testing of unfamiliar genes? 2). Do different results (i.e., negative, positive, or
VUS) affect patient anxiety levels in the post-results period? 3). Is patient anxiety
affected by the specific gene in which the mutation or VUS is identified? The study
included women diagnosed with breast cancer and considered at high risk for a hereditary
cancer syndrome due to age or family history. Participants completed a baseline StateTrait Anxiety (STAI) questionnaire at the pre-test genetic counseling session, and
completed the same STAI questionnaire and a Multidimensional Impact of Cancer Risk
Assessment (MICRA) questionnaire after the post-results discussion. Twenty individuals
participated, of which 17 patients completed the baseline STAI tool. Nine participants
completed all questionnaires, yielding five participants with negative results, two with
1

Alfonso, A., Walker, P., Chapman, C., & Dobek, W. To be submitted to Journal of Genetic Counseling
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positive results, and two with VUS results. Two participants with negative results showed
significant baseline anxiety levels which decreased in the post-results period. The
positive and VUS result groups showed non-significantly increased mean anxiety levels
by STAI. Differences in anxiety between those with positive results and those with
negative results trended toward significance. Two individuals with positive mutation
results in genes other than BRCA1 and BRCA2 showed higher post-results anxiety levels
on the MICRA scale than did two participants with VUS results. The study was limited
by sample size. A larger multi-site study is planned to clarify anxiety, distress, and
uncertainty parameters to help guide genetic counselors in their approach to psychosocial
aspects of multiplex cancer genetic testing.
2.2 Introduction
Five to ten percent of breast cancer cases are caused by an inherited germline
mutation that confers an increased lifetime susceptibility to breast cancer development
and may be accompanied by increased susceptibility to ovarian, prostate, pancreatic, and
other specific cancers (USPSTF, 2009). The most common genes currently known to be
associated with an increased lifetime risk for breast cancer are the BRCA1 and BRCA2
genes. The effects of various deleterious mutations in these two genes lead to a condition
known as Hereditary Breast and Ovarian Cancer syndrome (HBOC). Other genes have
been reported which have been shown to be associated with cancer predisposition
syndromes in which a high risk for breast cancer is present. Some genes have clear
associated lifetime risks, as well as guidelines for screening, including TP53, PTEN,
CDH1, and STK11. Mutations in PALB2, CHEK2, ATM, NBN, BARD1, MRE11A,
RAD50, RAD51C, and BRIP1 genes have been linked to a genetic predisposition to breast
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cancer, but do not have well defined screening guidelines. Molecular testing for breast
cancer predisposition syndromes often influences healthcare decisions involving risk
reducing surgical measures. Prophylactic mastectomies have been shown to reduce the
risk of breast cancer by about 90% (Rebbeck et al., 2004). Prophylactic oophorectomies
have been shown to reduce the risk for ovarian cancer by up to 96% (Chang-Claude et al.,
2007), and to reduce the risk for breast cancer by about 50% when performed in
premenopausal women (Eisen et al., 2005; Kauff et al., 2008; Rebbeck et al., 1999,
2009). Uptake of risk-reducing surgery is a complex decision based on clinical factors
such as lifetime risk, age, and genetic test results, and often times on emotional factors
such as the death of a relative due to cancer and time since genetic testing (Evans et al.,
2009; Samama et al., 2014). Hawley et al. stated that the strongest influencing factor in
this decision is clinical genetic test results (2014).

Possible genetic test results include a negative result, a known deleterious mutation
(positive result), or a variant of uncertain significance (VUS) result. Several studies have
attempted to explore the psychological impacts of genetic test results. Negative test
results from BRCA1 and BRCA2 genetic testing have been shown to significantly reduce
perceived risk and distress when compared to those patients who received a positive
mutation result (Croyle et al., 1997; Schwartz et al., 2002). Furthermore, patients who
received a positive result typically experience heightened distress after disclosure about
their risk for cancer, while non-carriers have shown decreased psychological distress
(Meiser et al., 2002; van Roosmalen et al., 2004). Rini et al. reported that patients who
received VUS results have experienced decisional conflicts regarding prophylactic
measures for risk reduction (2009). While patients with a VUS result were more likely to
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overestimate their associated cancer risk than patients who received a positive result,
those receiving a VUS results were also more likely to have infrequent screening than
those who received a positive result (Vos et al., 2012). VUS results were more likely to
generate inappropriate recommendations regarding patient care by the physician (Plon et
al., 2011). Richter et al. recommended that the field would benefit from additional
education for referring physicians to make them aware of the possibility of VUS results
as well as the associated clinical uncertainty (2013).
We explored the differences between anxiety levels for patients who participated in
classic cancer genetic testing for a single hereditary breast cancer syndrome to those who
chose cancer genetic testing by multiplex cancer genetic testing for multiple hereditary
breast cancer predisposition syndromes. This study explored three areas: the overall
anxiety changes associated with classic genetic testing versus anxiety associated with
multiplex cancer genetic testing; how different results can affect levels of anxiety; and if
patient anxiety is affected by the gene in which a genetic change was found.
2.3 Materials and Methods
2.3.1 Participants. This study targeted adult women and men at high risk for a
hereditary breast cancer syndrome based on personal and family history. Participants
were invited to participate in the study if they met the following criteria:


Women or men who had been clinically diagnosed with breast cancer and who
qualified for genetic testing related to HBOC due to personal and/or family
history of cancer, based on the most recent guidelines from the National
Comprehensive Cancer Network (NCCN, 2014),



Participants who were fluent in English,
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Participants with recognized competence to read and understand the written
material.

Participants were excluded from the study if any of the following criteria were met:


Individuals who did not have a clinical diagnosis of breast cancer,



Individuals undergoing targeted testing for a known familial mutation,



Individuals who did not qualify for genetic testing, based on the most recent
Guidelines from NCCN, 2015,



Participants whose reading comprehension was judged insufficient to understand
the questionnaire information,



Individuals not fluent in English.

2.3.3 Study Measures. Demographic questions collected information regarding the
participants’ gender, ethnicity, highest level of education achieved, and number and
gender of biological children were collected.
2.3.3.1 State Trait Anxiety Inventory. The 20-item State-Trait Anxiety Inventory
(STAI) questionnaire (See Appendix B) was used to establish a baseline anxiety level
among participants at the time of genetic testing, following pre-test genetic counseling.
The post-results STAI questionnaire was provided approximately one week following the
discussion of the patient’s genetic test results. These paired surveys evaluated possible
changes in levels of anxiety experienced before and after genetic test results were
reported. In this pilot study, STAI responses were obtained over the phone by the
principal investigator. The statements on the STAI questionnaire were read to the
participants, and they were asked to choose which Likert scale response best matched
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their current emotional state. A weighted STAI value of 47 or greater was indicative of
statistically significant anxiety in either instance.
2.3.3.2 Multidimensional Impact of Cancer Risk Assessment. The Multidimensional
Impact of Cancer Risk Assessment (MICRA) Scale was used to examine levels of
distress among participants following their genetic test result disclosure (Cella et al.,
2002). Permission to use the MICRA scale for this study was granted by the
questionnaire’s lead author. The MICRA questionnaire was provided to participants
whose genetic test results included a positive result or VUS finding, but not to patients
with a negative result. The statements as found on the MICRA questionnaire (see
Appendix C) were read to the participants over the phone by the study’s principal
investigator approximately one week following results disclosure. Participants were
asked to choose which Likert scale response best matched their current emotional state
regarding their genetic test results. We calculated the mean and standard deviation of the
four MICRA score values of participants with positive or VUS results. Typical range of
statistical significance would be plus or minus 0.5 standard deviation of the mean in a
large group of participants who received negative results (D. Cella, personal
communication, March, 2015).
A brief section of Likert scale questions assessing the patient’s understanding of their
results, as well as how they felt their results would influence their healthcare management
was included. These Likert scale questions used a 1 to 4 scale of Strongly Disagree to
Strongly Agree. These questions also assessed with whom, if anyone, the patient intended
to share her results.
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2.3.3 Study Methods. Patients who underwent initial genetic counseling and who
qualified for genetic testing for one or more hereditary cancer syndromes were invited to
participate in the study. At the end of the initial genetic counseling session, and prior to
genetic testing, eligible patients were informed of the study and then given the letter of
study introduction by their genetic counselor. At that time, participants were given a print
copy of the baseline State-Trait Anxiety Inventory (STAI) to be completed in the waiting
room or to be taken home and returned to our center via a self-addressed postage-paid
envelope. Blood was drawn for genetic testing typically on the same day and shipped to
the appropriate laboratory. Results of genetic testing were provided to the participants by
telephone. Patients with a VUS or positive result were encouraged to return for a postresults counseling session. At least one week following the date on which the
participant’s genetic test results were discussed, the participant was called by the
principal investigator to schedule a time when the two follow-up questionnaires (the postresult STAI and the MICRA Scale) could be administered over the telephone as
explained above.
Each participant was assigned a unique alpha-numeric identifier (e.g., A101,
A102, A103, etc.) that was coded on each of the three questionnaires for confidential
comparison of anxiety experienced by the participant at each stage of the study. The
genetic counselor was provided a preconfigured electronic spreadsheet for recording
patient information, genetic test selected, and test results. Personal identifying
information and genetic test results were removed from the study spreadsheet by the
genetic counselor before contact information was provided to the principal investigator.
The patient information given to the principal investigator for administering the
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questionnaires included only the patient’s phone number and surname. Personal
information was destroyed by shredding after phone calls were completed. This research
study was approved by the Institutional Review Board, Office of Research Compliance,
of the University of South Carolina, Columbia, SC, in September, 2014.
2.3.4 Data Analysis. Data from patient demographic questions were analyzed using
descriptive analysis, including percentages, proportions, means, and ranges of values. See
Table 2.1 below for specific demographic information.
The results of the baseline STAI questionnaire for anxiety levels were scored
according to instructions provided with that tool, resulting in a State Anxiety Score for
each participant. Anxiety scores were analyzed by results grouping and compared by
paired sample t-test for possibly significant differences in anxiety state before genetic
testing and after results were reported to them to ascertain possible differences in anxiety
levels due to the type of result received.
The results of the MICRA scale were analyzed according to the instructions provided
with that tool. The scale results in three subscales including Distress, Uncertainty, and
Positive Experiences. The individual composite scores were used in the following
quantitative analyses where appropriate and were analyzed by descriptive statistics.
In addition, a chi-square goodness-of-fit test was used to analyze the scores from the
MICRA questionnaire using gene identity and positive or VUS results as variables.
Mann-Whitney U-test was conducted on this nonparametric data set to determine if
there were differences in anxiety scores measured by the MICRA questionnaire between
the negative (n = 5), positive (n = 2), and VUS (n = 2) subgroups.
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Table 2.1 Participant Demographics and Anxiety Levels (N = 17)

Variable
Diagnosed in past 5 years

Age

n Response (%)
10 Yes
(59%)
7 No
(41%)
2
4
5
4
2

30-39
40-49
50-59
60-69
70-79

(12%)
(24%)
(28%)
(24%)
(12%)

Gender

17 Female

Ethnicity

13 Caucasian (76%)
3 Black
(18%)
1 Hispanic
(6%)

Education

Marital Status

Children

2
5
3
5
2

(100%)

High School (diploma or GED) (12%)
Some College
(29%)
Associate's Degree
(18%)
Bachelor's Degree
(29%)
Beyond Bachelor's Degree
(12%)

13 Married
3 Divorced
1 Remarried

(77%)
(18%)
(6%)

2 Daughters only (12%)
4 Sons only
(24%)
11 Both
(65%)

Kruskal-Wallis analysis was conducted to determine if there were differences in
anxiety amongst the three groups of participants (negative, positive, and VUS findings by
genetic testing) as assessed by the MICRA questionnaire.
2.4 Results
Seventeen participants completed the baseline STAI questionnaire and were enrolled
in the study. Table 2.1 provides the sociodemographics of the 17 individuals who
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completed the baseline questionnaire. All participants received the post-result
questionnaire packet, which included the post-result STAI and the MICRA
questionnaires, to be completed at home and returned to our center by pre-paid envelope.
Nine participants completed all questionnaires, yielding a 53% response rate. Of these
nine participants, all had undergone multiplex cancer genetic testing. Five (56%) received
negative results (no mutation and no VUS), two (22%) received positive results of
pathogenic mutations, and two (22%) received VUS results.
The mean weighted score of the post-result STAI questionnaire was 37 (SD = 9.6)
across all groups. Among participants who received a negative result (n = 5), the mean
weighted score of the baseline STAI questionnaire was 39 (SD = 11, range = 28 to 50)
and the mean weighted score of the post-result STAI questionnaire was 34 (SD = 10,
range = 24 to 44). Among participants who received a negative result, paired sample ttest showed a mean decrease in anxiety score of 4.8 (SD = 13.85, p = .808). Two of the
five participants with negative results displayed statistically significant anxiety by
baseline STAI (47 and 53, respectively). Both showed decreased anxiety scores on the
post-results STAI (43 and 31, respectively) following a negative result.
The two participants who received a positive result differed in the specific genes
found to have deleterious mutations. The individual with the ATM mutation was also
found to have a VUS in the BMPR1A gene. This individual’s baseline anxiety score was
25 and increased to 53 in the post-results period, which is considered statistically
significant. The second participant, who received a positive mutation result in the TP53
gene, had weighted anxiety scores of 34 (baseline) and increased to 40 (post-results),
which did not reach statistical significance for anxiety. Among the two participants who
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received a positive mutation result, paired sample t-test showed a mean increase in
anxiety score of 17 (SD = 15.56, p = .366).
For the two participants who received a VUS result, the weighted scores of the initial
STAI questionnaire were 20 and 27. Weighted scores of the STAI post-results
questionnaire were 20 and 40 respectively, showing an increase in anxiety in one of two
participants and no change in the other. For these two participants, paired sample t-test
showed a mean increase in anxiety score of 6.5 (SD = 9.19, p = .000), which was
statistically significant; these results are shown in Figure 2.1.
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Participant and Result

Figure 2.1 Weighted Baseline and Post-Results STAI Scores
Note: Values of 47 or greater are considered a statistically significant level of anxiety.

Using the Mann-Whitney U-test, comparison of the median MICRA scale scores
from the positive mutation group (mean rank = 84.5) and the VUS group (mean rank =
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34.5) did not differ significantly, U = .000, z = -1.549, p = .121. Comparison of the
median values of the negative mutation group (mean rank = 23.8) and the VUS group did
not differ significantly, U = 3.00, z = -.782, p = .434. Comparison of the median values of
the positive mutation group and the negative group trended toward significance, U =
.000, z = -1.954, p = .051.
Using Kruskall-Wallis analysis, anxiety scores from the MICRA questionnaire
increased from the negative result group (Median = 19), to the VUS group (Mean =
34.5), to the positive group (Mean = 84.5). When cross-tabulated by chi-squared analysis,
differences between MICRA scores of the three groups were not significant, but appeared
to be trending toward significance, χ2(9) = 4.612, p = .100. Comparison of baseline STAI
and post-result STAI scores among the three groups did not demonstrate significantly
different associations of anxiety levels based on test results, χ2(9) = 2.968, p = .227 and
χ2(9) = 2.062, p = .357 respectively.
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Figure 2.2 A Pilot study Example of MICRA Scale Results
Note: Statistically significant levels could not be calculated due to small sample size.
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Knowledge questions regarding how the participants planned to use their results
were asked of those participants who received a VUS or a positive mutation result. The
responses available to each question were, Strongly Disagree; Somewhat Disagree;
Somewhat Agree; and Strongly Agree. Only one participant with a VUS result
responded. Table 2.2 shows the responses from this participant, and Table 2.3 shows the
responses from the two participants with positive mutation results.
Table 2.2 Participant Intention to Use VUS results
Statement
I felt well-prepared from my first counseling
session about the possibility of getting a VUS
result.

Responses from Participants with
VUS Result
Somewhat agree

When I got the VUS result, I felt more
anxious about the result than I thought I
would.

Somewhat agree

I expect that my doctors will help me make
healthcare decisions based on my VUS result.

Strongly agree

I intend to share my VUS results with my
children so that they can be tested.

Strongly agree

I intend to share my VUS results with my
other family members (parents, sisters,
brothers, aunts/uncles/ cousins) so that they
can be tested.

Strongly agree

Why or why not would you share your VUS
result?

“I want my other family members to have the
choice to know it that are positive or
negative and to be as proactive as possible in
making decisions about their lives based on
the results [sic]”
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Table 2.3 Participants’ Intention to use Positive Mutation Results
Statement
I felt well-prepared from my first counseling
session about the possibility of getting a
positive mutation result.

Response from Participants with
Positive Mutation Result
1) Somewhat agree
2) Somewhat agree

When I got the positive mutation result, I felt
more anxious about the result than I thought I
would.

1) Strongly agree
2) Strongly agree

I expect that my doctors will help me make
healthcare decisions based on my positive
mutation result.

1) Strongly agree
2) Strongly agree

I intend to share my positive mutation results
with my children so that they can be tested.

1) Strongly agree
2) Strongly agree

I intend to share my positive mutation results
with my other family members
(parents, sisters, brothers, aunts/uncles/
cousins) so that they can be tested.

1) Strongly agree
2) Strongly agree

Why or why not would you share your
positive mutation result?

1) “I will share my result so my family can
be informed and watch for warning signs”
2) No response

2.5 Discussion
Data collected for analysis during this pilot study often did not meet statistical
significance by analytical methods primarily due to sample size. We note that we are
reporting VUS and mutation results in genes other than BRCA1 and BRCA2 in this pilot
study. A full study is planned and will be expanded to multiple sites with a greater
number of participants anticipated. We expect that increased participation will help to
clarify answers to the goals set forth in this study. Initial data on this small sample
supports previous studies conducted by Croyle, Smith, Botkin, Baty, & Nash (1997) and
Schwartz et al. (2002) which found that negative genetic test results lead to significantly
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reduced perceived risk and distress when compared to those who received a positive
mutation result from BRCA1 or BRCA2 genetic testing. However, our participants
underwent multiplex cancer genetic testing of 21 to 29 genes for each individual.
Analysis of data collected during our pilot study showed that the changes in the levels of
anxiety experienced by the negative group and the mutation positive group trended
toward significance, suggestive of a similar association as reported by the above authors
when their participants receive a positive test result. Additionally, analysis of differences
in distress and anxiety between the negative, positive, and VUS result groups, as
measured by the MICRA questionnaire, trended toward significance.
O’Neill et al. (2009) previously reported that patients who receive an uncertain
result (i.e., VUS) have been shown to have increased anxiety. A single participant from
our initial data displayed a similar association, as self-reported anxiety for this individual
was elevated between baseline and post-result STAI. The second VUS participant had no
reported increase in self-reported anxiety between initial and post-result STAI. However,
neither participant receiving a VUS result had clinically significant anxiety levels. Data is
also supportive of previous findings by Smith et al. (2009) which reported that patients
who were found to have a VUS had increased anxiety but markedly less so than those
who received a positive result. In our larger study, we hope to have sufficient
participation to analyze subgroups of the MICRA questionnaire, which include distress,
uncertainty, and positive value of cancer genetic counseling, with enough participants to
find statistical significance of responses using the subgroup scores.
Baseline anxiety scores ranged dramatically among participants, even in the group
with negative results, and scores were sometimes higher at the time of pre-test genetic
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counseling than after results had been reported. Two participants displayed statistically
significant anxiety levels immediately following genetic testing. Interestingly, these
participants received negative results and displayed a decrease in anxiety between
baseline and post-result STAI questionnaires. We suggest that these initially high anxiety
reports from patients at their first genetic counseling session may be due to a variety of
factors. In our clinic, most participants were seen within two weeks of their initial
diagnosis of breast cancer and had not yet established a treatment plan with their surgeon
and/or oncologist. This time-related factor, could likely influence both distress and
anxiety. Some participants verbalized that the speed with which they were scheduled for
various appointments was too rapid to adequately process all of the information, while
others remarked that they just wanted to move on to surgery and have the cancer removed
as quickly as possible (P. Walker, personal communication, March, 2015). Likewise,
some patients may have been very anxious about many other factors during this period
that are unrelated to their genetic testing but may accompany a cancer diagnosis.
Examples from patients in general include anxiety about their daughter’s genetic status,
insurance coverage, financial hardship, and lack of family or social support.
Among participants who completed all parts of the survey, insufficient data exists
to analyze how changes in anxiety are affected by the gene in which a finding is made.
The participant with a deleterious mutation in the TP53 gene was the only participant to
reach statistically significant anxiety on the post-result STAI questionnaire. We note that
clear guidelines and clinical management recommendations exist for post-results genetic
counseling are available for TP53 mutation carriers. This participant displayed a smaller
increase in anxiety than the participant with both a positive result in the ATM gene and a
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VUS result in the BMPR1A gene. It is interesting to note that the participant with both a
positive mutation result and a VUS result additionally had a higher composite score
related to genetic test results as measured by the MICRA questionnaire. The lack of
clearly defined risks of a second breast cancer and lack of screening guidelines for
mutation carriers of the ATM gene may have added to the patient’s anxiety, as well as the
uncertainty around a VUS result. In some individuals, the finding of two results
simultaneously could be unsettling and increase their uncertainty and anxiety. We note
that both patients receiving positive results appeared to have significantly higher MICRA
scores that those who received VUS results (see Figure 2.2), although we could not
calculate a cut-off for statistically significant levels of anxiety on the MICRA score due
to small sample size. In the upcoming study, we expect that we will see sufficient
examples of positive results and VUS results to support our hypothesis and to compare
anxiety, distress, uncertainty, and positive value scores with those received from
individuals found to have BRCA1 and BRCA2 positive and VUS results.
It is interesting to note in tables 2.2 and 2.3 that statements of the two participants
who received positive results and the participant with a VUS result were similar for the
most part. These participants reported feeling somewhat, but not entirely, prepared for
receiving their respective results after their first genetic counseling session. This
retrospective perception of being somewhat unprepared for a positive result in patients
who receive positive or VUS results would likely be realistic to each person, as typically
patients expect to get negative results. These few results are anecdotal in this small
study, and we will depend on our larger study to help us clarify information in this area.

36

Participants stated that they felt strongly that their doctors would use their results
to help make healthcare decisions. This statement by the VUS group is interesting as
VUS findings, by virtue of their “uncertain significance,” have no recommendations for
changes to medical management. The statement in Table 2.2 “I want my other family
members to have the choice to know it that are positive or negative… [sic]” may simply
require further clarification, but it may suggest that patients do not fully or accurately
comprehend the implications of a VUS result regarding their own risk and/or healthcare
management. This finding is supported by the findings reported by Richter et al., (2013),
in which they found that incorrect risk recall was higher in patients who had received
VUS results than in patients with either negative or positive genetic test results.
One factor not explored that may affect changes in anxiety might be educational
material regarding the gene in which a change is discovered. Materials provided by the
health care professional or obtained by the patient through independent research, may
help to ease, in some patients, feelings of anxiety and distress associated with a VUS or
positive result. However, other patients may increase their own anxiety by searching for
too much information which is not generally available or may be anecdotal and yet to be
understood about many of the genes included in multiplex cancer genetic testing. Clearly,
new educational material for patients needs to be developed.
Further investigation, both in our own full study and by additional studies, is
crucial to explore the factors associated with increased anxiety related to genetic test
results. Given the changing landscape of genetic testing related to hereditary cancer
syndromes and the trend toward large multiplex cancer genetic testing, it is important to
know how different results might affect a patient’s psychological well-being.
37

Clarification regarding additional factors affecting levels of anxiety may help develop a
more complete pre-test counseling conversation or a more targeted conversation for
results discussion. Information gained by the full study is expected to be beneficial to
genetic counselors or other healthcare professionals to inform them how best to counsel
patients who choose testing from among multiple genetic test options. These findings are
likely to be significant to broader applications, as the field approaches whole genome
sequencing (WGS) and/or whole exome sequencing (WES) in the context of care for
individuals predisposed to developing breast cancer and cancers involved in other
hereditary cancer syndromes.
Study Limitations
Time constraints limited data collection to a single site, limiting both population size and,
theoretically, variation in population race and ethnicity. We were unable to analyze
differences in anxiety between those who chose BRCA1 and BRCA2 testing versus those
who chose multiplex cancer genetic testing. Small population size limited statistical
power. There was not an even distribution of participants in the negative, positive, and
VUS result categories, which is to be expected as negative results are more common.
Men undergoing genetic testing for hereditary breast cancer predisposition syndromes are
more uncommon than women, but an absence of male participants makes results less
generalizable. Obviously, the results from this pilot study are not generalizable to the
general population of breast cancer patients.
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Future Study
Moving forward from the pilot study will be critical towards fulfilling our research goals
about patient anxiety levels and genetic test results. We have enlisted two additional
centers for data collection, both larger than our own. A larger sample size should enable
us to answer the questions proposed by our study and may help to clarify what factors are
associated with increased anxiety in the context of breast cancer genetic testing. It may be
beneficial to consider additional questions to the initial questionnaire in order to further
search out extrinsic sources of anxiety that are not associated with their test results, such
as job stress, marital stress, or family demands.. These additional factors not previously
considered may help explain variation in initial anxiety scores. We also look forward to
the larger population to assess for accurate understanding of how patients understand
their VUS results, rather than speculating on anecdotal data.
Future Research
Qualitative studies would be of great value to explore the individual factors which
lead to an increased feeling of anxiety, as reported by participants. We theorize that
factors such as a recent diagnosis, unclear plan for treatment, financial concerns and
information/educational materials presented by the healthcare professional providing
pretest counseling may be contributing factors to heightened anxiety at the time of
testing. Additionally, exploration of specific factors which play a significant role in
causing heightened anxiety in the event of a positive or VUS finding is an area for further
investigations. It is possible that a state of heightened anxiety could be a driving force
behind compliance for recommended breast surveillance in mutation carriers, whereas
individuals with low anxiety levels may be lacking the motivation for frequent exams to .
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Further investigation regarding anxiety and adherence to recommended screening and/or
uptake of prophylactic surgical intervention could be of benefit to clinicians. as they
develop individual management plans to meet the needs their patients.
2.6 Conclusions
This study has interesting implications for the field of cancer genetic counseling, as well
as for other healthcare providers involved in ordering, reporting, and counseling patients
regarding genetic testing for hereditary cancer predisposition. We were unable to explore
the difference in anxiety experienced by those who undergo classic BRCA1/BRCA2
testing versus those who pursue multiplex cancer gene testing, as all participants in our
study chose multiplex testing. Similar to findings by previous studies, participants who
received a negative result were found to have a decreased overall anxiety, while those
who received a VUS or positive result were found to have an increased overall anxiety.
The levels of changes in anxiety experienced by the negative result group and the positive
result group approached statistical significance, even at small sample size. The gene in
which a mutation or VUS was found also appears to affect overall changes in anxiety,
although it is unclear at this time what specific factors are associated with this anxiety
causing effect (e.g., a lack of management guidelines for some genes or varying
associated lifetime risks). Further study using a larger clinical population is expected to
help further clarify the differences in anxiety experienced between those who undergo
classic BRCA1 and BRCA2 testing and those who undergo multiplex testing. Results from
a larger population may help us better understand what specific factors influence changes
in anxiety between patients with negative, positive, or VUS test results. If significant
differences are found in our larger study, the presentation of information pertaining to
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genetic testing options would ideally be tailored by genetic counselors for optimal
psychological patient support.

41

Chapter 3: Conclusions
This study has interesting implications for the field of genetic counseling, as well as for
other professions involved in ordering, reporting, and counseling patients regarding
genetic testing for hereditary cancer predisposition. We were unable to explore the
difference in anxiety experienced by those who undergo classic BRCA1/BRCA2 testing
versus those who pursue multiplex cancer gene testing as all participants in our study
chose multiplex testing. Similar to findings by previous studies, participants who
received a negative result were found to have a decreased overall anxiety, while those
who received a VUS or positive result were found to have an increased overall anxiety.
The difference in changes in anxiety experienced by the negative result group and the
positive result group approached statistical significance, even at small sample size. The
gene in which a mutation or VUS was found also appears to affect overall changes in
anxiety, although it is unclear at this time what specific factors are associated with this
anxiety causing effect (e.g. a lack of management guidelines for some genes or varying
associated lifetime risks). Further study using a larger clinical cohort may help to further
clarify the differences in anxiety experienced between those who undergo classic BRCA1
and BRCA2 testing and those who undergo multiplex testing. Results from a larger
population may help us better understand what specific factors influence changes in
anxiety between patients with negative, positive, or VUS test results. If significant
differences are found in our larger study, the presentation of information pertaining to
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genetic testing options would ideally be tailored for optimal psychological patient
support.
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Appendix A: Participant Introductory Letter
University of South Carolina School of Medicine
USC Genetic Counseling Program
Dear Potential Participant:
You are invited to participate in a graduate research study focusing on patient distress and
uncertainty regarding genetic testing for a personal history of breast cancer. I am a graduate
student in the genetic counseling program at the University of South Carolina School of
Medicine. My research investigates patient distress and uncertainty regarding the possible results
from genetic testing for hereditary cancer predisposition syndromes. The research involves
completing one survey during your initial counseling session when genetic testing is completed
and possibly a follow-up survey at a future time regarding your test results.
The surveys attempt to interpret your current emotional state, in regards to distress and
uncertainty, at the time of undergoing genetic testing and again at the time of results disclosure.
The surveys will include questions regarding your current emotional state as well as opinion
questions regarding genetic testing and results. Please answer all questions truthfully as there are
no right or wrong answers.
All responses gathered from the surveys will be kept anonymous and confidential. The results of
this study might be published or presented at academic meetings; however, participants will not
be identified.
Participants who include contact information will also be entered into a raffle to win a $25 Visa
gift card. If you are chosen, this prize will be sent to you at a later date, after having collected all
data. Your contact information will not be used for any other purposes beyond sending the raffle
prize if you have won.
Your participation in this research is voluntary. By completing the survey, you are consenting that
you have read and understand this information. At any time, you may withdraw from the study by
not completing the survey.
Thank you for your time and consideration to participate in this survey. Your responses may help
genetic counselors better serve patients who undergo similar genetic testing as you in the future.
If you have any questions regarding this research, you may contact either myself or my faculty
advisor, Peggy Walker, MS, CGC, using the contact information below. If you have any
questions about your rights as a research participant, you may contact the Office of Research
Compliance at the University of South Carolina at (803) 777-7095.
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Student Contact Information

Thesis Advisor Contact Information

Andrew Alfonso
Graduate Student, Master of Science in Genetic
Counseling
University of South Carolina, School of Medicine
Andrew.Alfonso@uscmed.sc.edu
(786) 205-2098

Peggy Walker
Genetic Counselor & Clinical Assistant Professor,
School of Medicine
Department of Obstetrics and Gynecology
University of South Carolina School of Medicine
Peggy.Walker@uscmed.sc.edu
(803) 545-5775
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Appendix B: 20-Item State Trait Anxiety Inventory
Self-Evaluation Questionnaire
A number of statements which people have used to describe themselves are given below.
Read each statement and then circle the appropriate value to the right of the statement to
indicate how you feel right now, that is, at this moment. There are no right or wrong
answers. Do not spend too much time on any one statement but give the answer which
seems to best describe your present feelings.

1.

I feel calm.

Not at All

Somewhat

Moderately So

Very Much So

2.

I feel secure.

Not at All

Somewhat

Moderately So

Very Much So

3.

I am tense.

Not at All

Somewhat

Moderately So

Very Much So

4.

I am strained.

Not at All

Somewhat

Moderately So

Very Much So

5.

I feel at ease.

Not at All

Somewhat

Moderately So

Very Much So

6.

I feel upset.

Not at All

Somewhat

Moderately So

Very Much So

7.

I am presently worrying
over possible
misfortunes.

Not at All

Somewhat

Moderately So

Very Much So

8.

I feel satisfied.

Not at All

Somewhat

Moderately So

Very Much So

9.

I feel frightened.

Not at All

Somewhat

Moderately So

Very Much So

10.

I feel comfortable.

Not at All

Somewhat

Moderately So

Very Much So

11.

I feel self-confident

Not at All

Somewhat

Moderately So

Very Much So
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12.

I feel nervous.

Not at All

Somewhat

Moderately So

Very Much So

13.

I feel jittery.

Not at All

Somewhat

Moderately So

Very Much So

14.

I feel indecisive.

Not at All

Somewhat

Moderately So

Very Much So

15.

I feel relaxed.

Not at All

Somewhat

Moderately So

Very Much So

16.

I feel content.

Not at All

Somewhat

Moderately So

Very Much So

17.

I am worried.

Not at All

Somewhat

Moderately So

Very Much So

18.

I feel confused.

Not at All

Somewhat

Moderately So

Very Much So

19.

I feel steady.

Not at All

Somewhat

Moderately So

Very Much So

20.

I feel pleasant.

Not at All

Somewhat

Moderately So

Very Much So

General Information About You
My Breast Cancer Diagnosis was made within the past 5 years: Yes No (please circle one)
What is your age? ___________
What is you gender?

Male

Female

(please circle one)

What is your ethnicity?
a. Caucasian
b. African-American
c. Hispanic
d. Native American
e. Asian
f. Other:_______________
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What is your highest level of education?
a. Did not complete high school
b. Completed high school (diploma of GED)
c. Some college
d. Associate’s degree
e. Bachelor’s degree
f. Beyond bachelor’s degree
Marital Status:
a. Single and never married
b. Married
c. Widowed
d. Separated
e. Divorced
f. With partner
g. Remarried
Do you have children?

Yes

No

(please circle one)

If you have young or adult children, please list the age of each child and their relationship to you.
Age __________________ Daughter

Son (please circle one)

Age __________________ Daughter

Son (please circle one)

Age __________________ Daughter

Son (please circle one)

Age __________________ Daughter

Son (please circle one)

Age __________________ Daughter

Son (please circle one)

Age __________________ Daughter

Son (please circle one)
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Appendix C: Multidimensional Impact of Cancer Risk Assessment (MICRA)
MICRA Scale about Cancer Risk Assessment
The questions below are about some specific responses you may have had after
receiving your genetic test results. Please answer every question in Section 1,
regardless of whether you were given a positive or negative test result. Please
indicate whether you have experienced each statement never, rarely, sometimes, or
often in the past week, by circling the corresponding number.
Section 1.
1.

Feeling upset about my test result.

Never

Rarely

Sometimes

Often

2.

Feeling sad about my test result.

Never

Rarely

Sometimes

Often

3.

Feeling anxious or nervous about my
test result.

Never

Rarely

Sometimes

Often

4.

Feeling guilty about my test result

Never

Rarely

Sometimes

Often

5.

Feeling relieved about my test result

Never

Rarely

Sometimes

Often

6.

Feeling happy about my test result

Never

Rarely

Sometimes

Often

7.

Feeling a loss of control.

Never

Rarely

Sometimes

Often

8.

Having problems enjoying life because
of my test result.

Never

Rarely

Sometimes

Often
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9.

Worrying about my risk of getting
cancer (or getting cancer again if you
have ever been diagnosed with
cancer).

Never

Rarely

Sometimes

Often

10.

Being uncertain about what my test
result means about my cancer risk.

Never

Rarely

Sometimes

Often

11.

Being uncertain about what my test
result means for my child(ren) and/or
family’s cancer risk.

Never

Rarely

Sometimes

Often

Having difficulty making decisions
about cancer screening or prevention
(e.g., having preventive surgery or
getting medical tests done).

Never

Rarely

Sometimes

Often

13.

Understanding clearly my choices for
cancer prevention or early detection

Never

Rarely

Sometimes

Often

14.

Feeling frustrated that there are no
definite cancer prevention guidelines
for me.

Never

Rarely

Sometimes

Often

Thinking about my test results has
affected my work or family life.

Never

Rarely

Sometimes

Often

12.

15.
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Remember, we are talking about the past seven days.

Never

Rarely

Sometimes

Often

Feeling concerned about how my test
results will affect my insurance
status.

Never

Rarely

Sometimes

Often

17.

Having difficulty talking about my
test results with family members.

Never

Rarely

Sometimes

Often

18.

Feeling that my family has been
supportive during the genetic
counseling and testing process.

Never

Rarely

Sometimes

Often

Feeling satisfied with family
communication about my genetic test
result.

Never

Rarely

Sometimes

Often

Worrying that the genetic counseling
and testing process has brought about
conflict within my family.

Never

Rarely

Sometimes

Often

Feeling regret about getting my test
results.

Never

Rarely

Sometimes

Often

16.

19.

20.

21.

Section 2. If you have children, regardless of your test result, please answer questions #
22 and 23. Otherwise, please go to Section 3.

22.

Worrying about the possibility of my
children getting cancer.

Never

Rarely

Sometimes

Often

23.

Feeling guilty about possibly passing
on the disease risk to my child(ren).

Never

Rarely

Sometimes

Often
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Section 3. If you currently have cancer, or have had it in the past, please answer
questions # 24 and 25. Otherwise, please check this box  : Please go on to the next
page, Section 4.

24.

Feeling that the genetic test result has
made it harder to cope with my cancer.

Never

Rarely

Sometimes

Often

25.

Feeling that the genetic test result has
made it easier to cope with my cancer.

Never

Rarely

Sometimes

Often

Please continue the survey on page 3.
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Section 4. After this genetic counseling session, how do you think you will use these
genetic results that have been discussed with the genetic counselor?
A1. If you have received a POSITIVE result, please circle the best answer that shows your
opinion about how you feel now about getting this POSITIVE result. (If you received a VUS
result, please skip this question and answer Questions in B1 instead – See Below.)
1. I felt well-prepared from my first counseling session about the possibility of getting a
positive result.
Strongly
Disagree

Somewhat

Somewhat

Strongly

Disagree

Agree

Agree

2. When I got the positive result, I felt more anxious about the result than I thought I would.
Strongly
Disagree

Somewhat

Somewhat

Strongly

Disagree

Agree

Agree

3. I expect that my doctors will help me make healthcare decisions based on my positive
result.
Strongly
Disagree

Somewhat

Somewhat

Strongly

Disagree

Agree

Agree

4. I intend to share my positive result with my children so that they can be tested.
Strongly
Disagree

Somewhat

Somewhat

Strongly

Disagree

Agree

Agree

5. I intend to share my positive result with my other family members (parents, sisters,
brothers, aunts/uncles/cousins) so that they can be tested.
Strongly
Disagree

Somewhat

Somewhat

Strongly

Disagree

Agree

Agree

6. Why or why not would you share your POSITIVE result?
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If you have received a POSITIVE result, the survey is now complete. Please skip the following
questions in B1, found on page four, and proceed directly to our offer to participate in a
random drawing for a $25 gift card. Please fill-out the attached sheet regarding your contact
information. If you would not like to participate in the random drawing, please disregard the
final sheet.

B1. If you have received a VUS result, please circle the best answer that shows your opinion
about how you feel now about getting this VUS result.

7. I felt well-prepared from my first counseling session about the possibility of getting a VUS
result.
Strongly
Disagree

Somewhat

Somewhat

Strongly

Disagree

Agree

Agree

8. When I got the VUS result, I felt more anxious about the result than I thought I would.
Strongly
Disagree

Somewhat

Somewhat

Strongly

Disagree

Agree

Agree

9. I expect that my doctors will help me make healthcare decisions based on my VUS result.
Strongly
Disagree

Somewhat

Somewhat

Strongly

Disagree

Agree

Agree

10. I intend to share my VUS result with my children so that they can be tested.
Strongly
Disagree

Somewhat

Somewhat

Strongly

Disagree

Agree

Agree
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11. I intend to share my VUS result with my other family members (parents, sisters, brothers,
aunts/uncles/cousins) so that they can be tested.
Strongly
Disagree

Somewhat

Somewhat

Strongly

Disagree

Agree

Agree

12. Why or why not would you share your VUS result?
________________________________________________________________________
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